Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue and Photodynamic Therapy for Outpatient COVID-19
NCT04619290Phase 1Unknown
- Sponsor
- Hospital Regional Licenciado Adolfo López Mateos
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of methylene blue in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hospital Regional Licenciado Adolfo López Mateos. Primary endpoints: Change from baseline in Arterial oxygen saturation at 7 days and Days to clinical improvement at 7 days. Status: unknown.
02
Drugs
methylene blue
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04619290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619290.